ENGINEERING OF THE RECEPTOR BINDING REGION OF UPA

Information

  • Research Project
  • 3498149
  • ApplicationId
    3498149
  • Core Project Number
    R43GM040827
  • Full Project Number
    1R43GM040827-01A2
  • Serial Number
    40827
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/1/1990 - 35 years ago
  • Project End Date
    12/31/1990 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    1/1/1990 - 35 years ago
  • Budget End Date
    12/31/1990 - 34 years ago
  • Fiscal Year
    1990
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    12/25/1989 - 35 years ago

ENGINEERING OF THE RECEPTOR BINDING REGION OF UPA

uPA (urokinase type plasminogen activator) is a thrombolytic protease which has been implicated in certain non-thrombolytic physiological processes, most notable the invasive growth or migration of metastatic cells and of macrophages. The role of uPA in cell migration appears to involve binding of this protease to specific cell surface receptors. I hope to engineer uPA derived molecules which are proteolytically inactive and which bend with enhance avidity to the uPA receptor. These molecules may serve as competitive inhibitors of native uPA receptor binding and in this way be useful therapeutic agents by inhibiting physiological processes requiring receptor bound uPA. Towards achieving this end, I plan, in phase I of this project, to develop a uPA receptor binding assay. This assay will involve yeast secretion of uPA molecules onto nitrocellulose filters and probing of these filters with 1251-labeled, purified receptor molecules. The assay will be designed to be used in phase II of this project for rapid screening of yeast colonies secreting uPA molecules which have altered receptor binding. I also plan, in phase I to construct a library in E.coli of vectors with mutations within the cDNA encoding the receptor binding region of uPA. In phase II, I plan to screen this library and to follow strategies leading to the engineering of uPA molecules with enhanced receptor binding and to test the ability of these molecules to competitively inhibit binding by wild-type molecules. In collaboration with others, I plan to test the ability of these molecules as inhibitors of invasive cell migration.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    COLLABORATIVE RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02154
  • Organization District
    UNITED STATES